Full text is available at the source.
Abstract
Obesity is associated with chronic low-grade inflammation that contributes to residual cardiovascular risk.
- Inflammation is a central factor in the development of atherosclerosis.
- Incretin-based therapies may influence obesity-related inflammation through weight loss and metabolic improvements.
- Anti-inflammatory trials suggest that targeting inflammation could provide therapeutic benefits, although results vary by patient and context.
- Glucagon-like peptide-1 receptor agonists have shown potential to reduce inflammatory biomarkers and exert anti-atherosclerotic effects in preliminary studies.
- Human data on the efficacy of these therapies in modifying vascular inflammation are currently inconclusive.
- The roles of weight loss and metabolic changes in the effectiveness of incretin therapies remain uncertain.
Simplified